Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Conditions
Anovulation
Interventions
Anastrozole 1 mg, Anastrozole 5 mg, Anastrozole 10 mg, Clomiphene Citrate 50 mg, Clomiphene Citrate 100 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rockland, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Impact of Menstrual Phase on Oral Glucose Sensitivity

NCT06800690
Conditions
Ovulation, Menstruation
Interventions
Urinary Estrogen Level
Diagnostic Test
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 46 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Polycystic Ovary Syndrome, Infertility, Female
Interventions
May Health System
Device
Lead sponsor
May Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
19
States / cities
Encino, California • San Francisco, California • Tampa, Florida + 16 more
Conditions
Contraception, Ovulation Inhibition, Contraceptives, Oral
Interventions
EE20/DRSP (BAY86-5300), EE20/DRSP (YAZ, BAY86-5300)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,887 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
85
States / cities
Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 74 more
Conditions
Gestational Age, Time to Pregnancy, Early Pregnancy Loss
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
45 Years to 75 Years · Female only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers Results available

Folic Acid and Zinc Supplementation Trial (FAZST)

NCT01857310
Conditions
Pregnancy, Live Birth, Spontaneous Abortion
Interventions
5 mg folic acid and 30 mg elemental zinc, Placebo Comparator: Placebo
Dietary Supplement · Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 45 Years
Enrollment
2,370 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
4
States / cities
Chicago, Illinois • Iowa City, Iowa • Minneapolis, Minnesota + 1 more
Conditions
Suppression of Ovulation
Interventions
Nestorone®/Estradiol Contraceptive Vaginal Ring
Device
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
7
States / cities
Sacramento, California • New York, New York • Cincinnati, Ohio + 4 more
Conditions
Infertility, Infertility (IVF Patients), Infertility Assisted Reproductive Technology, Ovulation Ind
Interventions
Spanish-Speaking Provider
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 3 Interventional Results available

LutrePulse Hypogonadotropic Hypogonadism

NCT01976728
Conditions
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Interventions
Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump, Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
33
States / cities
Tempe, Arizona • San Francisco, California • Aurora, Colorado + 28 more
Conditions
Autoimmune Disease, Infertility, Premature Ovarian Failure
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Infertility, Miscarriage
Interventions
Creighton Model System in conjunction with Natural Procreative Technology (NPT)
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
5
States / cities
Baton Rouge, Louisiana • Gardner, Massachusetts • St Louis, Missouri + 2 more
Conditions
Compare Pregnancy Rates Between FSH Stimulation and FSH and, GnRH Antagonist
Interventions
Follistim administration, Follistim plus Ganirelix
Drug
Lead sponsor
Houston Fertility Institute
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Infertility
Interventions
Placebo, Dexamethasone
Drug
Lead sponsor
San Antonio Military Medical Center
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Conditions
Ovulation
Interventions
NES/E2 gel
Drug
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Completed No phase listed Observational

Hormonal Changes in Early Pregnancy

NCT00340028
Conditions
Pregnancy
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
25 Years to 35 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Research Triangle Park, North Carolina
Conditions
Female Infertility Due to Diminished Ovarian Reserve
Interventions
Human Growth Hormone, Follicle Stimulating Hormone
Drug
Lead sponsor
Center for Human Reproduction
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control

NCT01250210
Conditions
Ovulation Suppression
Interventions
levonorgestrel and ethinyl estradiol
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
11
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more
Conditions
Infertility, Female, Infertility
Interventions
Clomiphene
Drug
Lead sponsor
Neil Chappell
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
10 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Role of Estrogen in Luteinizing Hormone Surge and Ovulation

NCT01999569
Conditions
Ovulation Disorder, Ovarian Cysts
Interventions
Letrozole
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Polycystic Ovarian Syndrome
Interventions
Raloxifene, Clomiphene
Drug
Lead sponsor
Bruce Lessey
Other
Eligibility
18 Years to 36 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Greenville, South Carolina
Conditions
Functional Hypothalamic Amenorrhea, FHA
Interventions
Mibavademab, Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Phoenix, Arizona • West Hills, California • New Haven, Connecticut + 8 more
Conditions
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
Interventions
Semaglutide Injectable Product (Wegovy and/or Ozempic)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 35 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5mg, Meloxicam 15 mg, Placebo
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Completed Phase 3 Interventional Accepts healthy volunteers

Ovulation Incidence in Oral Contraceptive Users

NCT03106454
Conditions
Contraception, Ovulation
Interventions
Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate, Norethindrone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Los Angeles, California